The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1568
ISSUE 1568
March 25, 2019
Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
March 25, 2019 (Issue: 1568)
The FDA has approved a sublingual tablet (Nocdurna –
Ferring) and a nasal spray (Noctiva – Avadel) formulation
of desmopressin acetate for treatment of nocturia due to
nocturnal polyuria in adults who wake up ≥2 times per
night to void. Nocdurna and Noctiva are the first two
products to be approved in the US for this indication.
Higher-strength nasal spray and oral tablet formulations
of desmopressin (DDAVP, and others) have been available
for years for treatment of diabetes insipidus and primary
nocturnal enuresis (bedwetting in children). In 2007, the
indication for primary nocturnal enuresis was removed
from the labels of the nasal spray formulations because
their use resulted in 61 cases of hyponatremia-related
seizures, 2 of which resulted in death.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
Article code: 1568d
Electronic, downloadable article - $45
Article code: 1568d
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
